ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of NAC in Alleviation of Hangover Symptoms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02541422
Recruitment Status : Completed
First Posted : September 4, 2015
Results First Posted : May 30, 2018
Last Update Posted : May 30, 2018
Sponsor:
Information provided by (Responsible Party):
Holly Stankewicz, D.O., St. Luke's Hospital and Health Network, Pennsylvania

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Hangover Symptoms, NAC
Interventions: Dietary Supplement: N Acetyl Cysteine
Other: placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
62 people were enrolled however only 49 were included in the analysis due to not submitting their surveys or did not complete the first day of the study.

Reporting Groups
  Description
NAC First, Then Placebo Patients receiving NAC after drinking to breathalyzer value 0.1 and then completed the survey in the morning after drinking and then at a later date returned and drank again to BrAC level of 0.1 and received placebo then again completed the survey in the morning
Placebo First Then NAC Group Patients receiving placebo after drinking to breathalyzer value 0.1 and then completed the survey in the morning after drinking and then at a later date returned and drank again to BrAC level of 0.1 and received NAC then again completed the survey in the morning

Participant Flow for 2 periods

Period 1:   First Intervention
    NAC First, Then Placebo   Placebo First Then NAC Group
STARTED   23   26 
COMPLETED   23   26 
NOT COMPLETED   0   0 

Period 2:   Second Intervention
    NAC First, Then Placebo   Placebo First Then NAC Group
STARTED   23   26 
COMPLETED   23   26 
NOT COMPLETED   0   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
All Study Participants All study participants received the 2 interventions - NAC and placebo. The participants completed one intervention on one day and returned to complete the other intervention on a subsequent day.

Baseline Measures
   All Study Participants 
Overall Participants Analyzed 
[Units: Participants]
 49 
Age 
[Units: Participants]
Count of Participants
 
Participants Analyzed   49 
<=18 years      0   0.0% 
Between 18 and 65 years      49 100.0% 
>=65 years      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Participants Analyzed   49 
Female      18  36.7% 
Male      31  63.3% 
Race and Ethnicity Not Collected [1] 
[Units: Participants]
Count of Participants
  
[1] Race and Ethnicity were not collected from any participant.
Region of Enrollment 
[Units: Participants]
 
United States   
Participants Analyzed   49 
United States   49 


  Outcome Measures

1.  Primary:   Hangover Symptom Scale   [ Time Frame: 12 hours or less ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Holly Stankewicz, D.O.
Organization: St. Luke's University Health Network
phone: 610-360-2725
e-mail: holly.stankewicz@gmail.com


Publications of Results:

Responsible Party: Holly Stankewicz, D.O., St. Luke's Hospital and Health Network, Pennsylvania
ClinicalTrials.gov Identifier: NCT02541422     History of Changes
Other Study ID Numbers: SLHN 2015-27
First Submitted: September 1, 2015
First Posted: September 4, 2015
Results First Submitted: July 1, 2017
Results First Posted: May 30, 2018
Last Update Posted: May 30, 2018